(c) what is the position regarding overcharging of prices of Fefol and Fesofer and what has been done to punish the producer?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) (c) and (d) The Committee has referred to in part (a) of the question, fall under price control Category and prices of such formulations are revised as and when applications are received for price revision. However, the price of some Calcium and Iron formulations (single ingredient) falling under decontrolled category had been reduced due to Government's intervention as per details given below:

Sl. No.	Name of the Bulk Drugs/Formulation	Pack Size	Price fixed by the Co. after increasing it (Rs.)	Reduced price after Govt's intervention (Rs.)	% CHG.
1.	Calcium Syrup	200 ml	20.11	13.50	(—)32.9
2.	Calcium Injection	5×1 ml	23.63	12.75	(—)46.0
3.	Fersolate Tablets	500's	25.37	22.00	(—)13.3

(c) The required details to the extent available will be collected and laid on the table of the House.

Turnover of Psychotherapeutic drugs

@@@1357. SHRI P. N. SUKUL: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 111 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) whether it is a fact that the ten brands of Psychotherapeutic drugs accounted for a turnover of Rs. 15.40 crores according to ORG;

(b) whether it is also a fact that the actual sale of these drugs is of the order of Rs. 26 crores even in respect of these ten brands;

(c) whether it is also a fact that the total sale of psychotherapeutic drugs is over Rs. 70 crores per annum which makes them 4th leading group after Antibiotics, Vitamins and Analgesics; and

(d) how do they rank 4th in turnover as a group when the diseases for which they are used are not widely prevalent?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (d) Psychotherapeutic drugs have been excluded from price control based on the recommendations contained in the Supplementary Report of the Kelkar Committee. Sales turnover is not monitored by this Ministry.

Prices of drugs

£1398. SHRI SANTOSH KUMAR SAHU: Will the Minister of INDUSTRY be pleased to refer to answer to Starred Question 101 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) on what basis it has been concluded that as a matter of fact the prices

@@@Previously Unstarred Question 841 transferred from the 25th July, 1989.

£Previously Unstarred Question 842 transferred from the 25th July, 1989.

of drugs have come down considerably;

(b) what was the wholesale price index of medicines before August, 1987 when the revised policy was brought into effect and what is the wholesale price index now;

(c) what are the medicines for which the prices had come down and what were the revised prices and prices before DPCO, 1987 of each pack of formulation;

(d) what was the price of Deonil tablets before price decontrol and what is the price after price decontrol; and

(e) what were the prices of Prolution Injection, Salvigon Tablets, Actidil Tablets Acetron Tablets before DPCO 1987, their present price and percentage increase?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) and (c) The details of price decontrolled drugs where prices had been brought down due to Government's intervention is given at Annexure. [*See* Appendix CCI, Annexure No. 94] The prices before DPCO, 1987 are not readily available.

(b), (d) and (e) The required details to the extent available will be collected and laid on the Table of the House.

Identification of drugs in terms of sales turn-over

@1359. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1650 given in the Rajya Sabha on the 9th May, 1989 and state:

(a) whether it is a fact that the experts of the Ministry of Health and Family Welfare have discriminated in the matter of identifying drugs having sales turn-over of more than rupees fifty lakhs;

(b) whether it is also a fact that the turn-over of Cyproheptadine and Diphenoxylate Hcl are less than rupees fifty lacs;

(c) if so, on what basis the experts agreed to the price control of these drugs and exclusion of Oxyfedrine, Polymixin-B-Sulphate, Glipizide and Catopril; and

(d) what steps are being taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) No, Sir.

(b) Sales turnover is not monitored.

(c) and (d). The Committee has recommended retention of these drugs under price control due to concentration in the formulation market by 2 companies in the case Cyproheptadine and very high concentration of formulation market by one company in the case of Diphenoxylate. The remaining drugs referred to in the question were exempted from price contol under DPCO, 1987 on the basis of recommendations contained in the first report of the Kelkar Committee.

Price decontrolling of Timolol

@@1360. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1656 given in the Rajya Sabha on 9th May, 1989 and state:

(a) whether it is a fact that drugs like Timolol can be price decontrolled ignoring the aspect that this drug is required for the National Health Programme;

@Previously Unstarred Question 845 transferred from the 25th July, 1989

@Previously Unstarred Question 846 transferred from the 25th July, 1989.